Dyslipidaemia

Act Now for your ACS Patients

Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)

Overview of adherence data with LLT highlighting the most recent data with PCSK9i

Lipid management in patients with ACS/ASCVD

Improving Lipid Management for Patients Post-ACS

Identifying and treating patients with high Lipidaemia risk post-ACS

Atherosclerosis: Identifying risks and improving outcomes

Act Now for Your ACS Patients: Treat Aggressively, Combine and Start Early

Act Now for Your ACS Patients: Summary

Act Now for Your ACS Patients: Patient Identification

Public health recommendations for Lp(a) measurement

Lipid Management in Patients with Diabetes Mellitus

PCSK9i after hospital discharge for acute MI

Factors associated with time to PCSK9i initiation following hospital discharge for acute myocardial infarction.

Possible Challenges Post One Year of ESC/EAS Guidelines

Relationship Between LDL-C LLTs and Risk of Stroke

Lp(a) as ASCVD risk factor

The role of the patient in Achieving LDL-C Target

Cardiovascular diseases (CVDs) are the leading cause of death globally¹

According to the World Health Organization, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths¹. Of these deaths, 85% were due to myocardial infarction or stroke¹. A CV event is a highly traumatic experience for patients and their families². It takes a heavy emotional toll, brings widespread disability and significantly impedes quality of life^3,4.

PCSK9i and Prevention of CVD

The synopsis of a Cochrane Systematic review on PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.

Cardiovascular Disease in Saudi Arabia: Facts and the Way Forward

Act Now for Your ACS Patients: Optimize Your ACS Pathway

Approach for Patients with CAD: Focus on LDL-C Control

Approach for Patients with PAD and T2D: Focus on LDL-C Control

ACC/AHA vs ESC/EAS LDL–C recommendations for residual risk reduction in ASCVD: A simulation study from Da Vinci

Atherosclerotic Cardiovascular Disease Risk Assessment

Achievement of lipid modification goals with Statins & Ezetimibe